BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguang SH, Wu CK, Liang CM, Tai WC, Yang SC, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Hsu PI, Wu DC, Chuah SK, Hsu CN. Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. Int J Environ Res Public Health 2018;15:E2655. [PMID: 30486324 DOI: 10.3390/ijerph15122655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Terashima T, Higashibeppu Y, Yamashita T, Sakata Y, Azuma M, Fujimoto K, Munakata H, Ishii M, Kaneko S. Treatment patterns and medical costs after hepatectomy in real-world practice for patients with hepatocellular carcinoma in Japan. Hepatol Res 2021. [PMID: 34288302 DOI: 10.1111/hepr.13701] [Reference Citation Analysis]
2 Chu SS, Kuo YH, Liu WS, Wang SC, Ho CH, Chen YC, Yang CC, Wu HC. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Sci Rep 2021;11:1614. [PMID: 33452421 DOI: 10.1038/s41598-021-81176-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Skill NJ, Butler J, O’brien DC, Kays JK, Kubal CA, Liangpunsakul S, Ninad N, Maluccio MA. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma. Transplantation Proceedings 2019;51:1907-12. [DOI: 10.1016/j.transproceed.2019.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL, Hu H. Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review. Front Public Health 2022;10:801981. [PMID: 35530735 DOI: 10.3389/fpubh.2022.801981] [Reference Citation Analysis]
6 Wu J, Liu C, Wang F. Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China. Front Public Health 2021;9:742355. [PMID: 34805067 DOI: 10.3389/fpubh.2021.742355] [Reference Citation Analysis]
7 Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]